Literature DB >> 35177789

Lysine-specific demethylase 1 as a corepressor of mineralocorticoid receptor.

Nao Kohata1, Isao Kurihara2,3, Kenichi Yokota1, Sakiko Kobayashi1, Ayano Murai-Takeda1, Yuko Mitsuishi1, Toshifumi Nakamura1, Mitsuha Morisaki1, Takahide Kozuma1, Takuto Torimitsu1, Miki Kawai1, Hiroshi Itoh1.   

Abstract

Mineralocorticoid receptor (MR) and its ligand aldosterone play a central role in controlling blood pressure by promoting sodium reabsorption in the kidney. Coregulators are recruited to regulate the activation of steroid hormone receptors. In our previous study, we identified several new candidates for MR coregulators through liquid chromatography-tandem mass spectrometry analysis using a biochemical approach. Lysine-specific demethylase 1 (LSD1) was identified as a candidate. The relationship between LSD1 and salt-sensitive hypertension has been reported; however, the role of MR in this condition is largely unknown. Here, we investigated the functions of LSD1 as a coregulator of MR. First, a coimmunoprecipitation assay using HEK293F cells showed specific interactions between MR and LSD1. A chromatin immunoprecipitation study demonstrated LSD1 recruitment to the gene promoter of epithelial Na+ channel (ENaC), a target gene of MR. Reduced LSD1 expression by treatment with shRNA potentiated the hormonal activation of ENaC and serum/glucocorticoid-regulated kinase 1, another target gene of MR, indicating that LSD1 is a corepressor of MR. In an animal study, mice with kidney-specific LSD1 knockout (LSD1flox/floxKSP-Cre mice) developed hypertension after a high-salt diet without elevation of aldosterone levels, which was counteracted by cotreatment with spironolactone, an MR antagonist. In conclusion, our in vitro and in vivo studies demonstrated that LSD1 is a newly identified corepressor of MR.
© 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.

Entities:  

Keywords:  Aldosterone; Corepressor proteins; Hypertension; Lysine-specific demethylase 1; Mineralocorticoid receptors

Mesh:

Substances:

Year:  2022        PMID: 35177789     DOI: 10.1038/s41440-022-00859-7

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  41 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

Review 2.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

3.  Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.

Authors:  Mitsuhiro Nishimoto; Hiroshi Ohtsu; Takeshi Marumo; Wakako Kawarazaki; Nobuhiro Ayuzawa; Kohei Ueda; Daigoro Hirohama; Fumiko Kawakami-Mori; Shigeru Shibata; Miki Nagase; Masashi Isshiki; Shigeyoshi Oba; Tatsuo Shimosawa; Toshiro Fujita
Journal:  Hypertens Res       Date:  2019-01-11       Impact factor: 3.872

4.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

5.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 6.  Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.

Authors:  Hirotaka Shibata; Hiroshi Itoh
Journal:  Am J Hypertens       Date:  2012-01-19       Impact factor: 2.689

7.  Epidermal growth factor receptor/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization.

Authors:  Yuko Mitsuishi; Hirotaka Shibata; Isao Kurihara; Sakiko Kobayashi; Kenichi Yokota; Ayano Murai-Takeda; Takeshi Hayashi; Rie Jo; Toshifumi Nakamura; Mitsuha Morisaki; Hiroshi Itoh
Journal:  Mol Cell Endocrinol       Date:  2018-01-31       Impact factor: 4.102

8.  High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C β Signaling.

Authors:  Takeshi Hayashi; Hirotaka Shibata; Isao Kurihara; Kenichi Yokota; Yuko Mitsuishi; Kennosuke Ohashi; Ayano Murai-Takeda; Rie Jo; Takako Ohyama; Masaya Sakamoto; Katsuyoshi Tojo; Naoko Tajima; Kazunori Utsunomiya; Hiroshi Itoh
Journal:  Int Heart J       Date:  2017-09-30       Impact factor: 1.862

9.  Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease.

Authors:  Shigeru Shibata; Miki Nagase; Shigetaka Yoshida; Wakako Kawarazaki; Hidetake Kurihara; Hirotoshi Tanaka; Jun Miyoshi; Yoshimi Takai; Toshiro Fujita
Journal:  Nat Med       Date:  2008-11-23       Impact factor: 53.440

10.  CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor.

Authors:  Kenichi Yokota; Hirotaka Shibata; Isao Kurihara; Sakiko Kobayashi; Ayano Murai-Takeda; Hiroshi Itoh
Journal:  Hypertens Res       Date:  2020-10-19       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.